PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your source for the latest clinical literature updates. Today, we’re discussing a study comparing the biosimilar ustekinumab FYB202 with reference ustekinumab in moderate-to-severe plaque psoriasis. Seth, great to have you here.
Seth: Thanks, Britany. Biosimilars are increasingly important, especially for chronic conditions like psoriasis where biologics can be costly. This study addresses key clinical questions.
Britany: Moderate-to-severe plaque psoriasis affects 2 to 3 percent globally. Many patients need systemic biologics for control. Ustekinumab, an IL-12/23 monoclonal antibody, is a proven effective and safe treatment.
Seth: But high biologic costs limit access. Biosimilars like FYB202 may offer similar benefits at lower cost, but robust evidence is needed to confirm equivalence in efficacy, safety, and immunogenicity.
Britany: Clinicians worry about switching from reference to biosimilar—whether it affects outcomes or immunogenicity. This study includes a switch substudy to address that.
Seth: The patients were adults with moderate-to-severe plaque psoriasis who had inadequate response or intolerance to at least one systemic therapy—those who benefit most from affordable biologics.
Britany: Regulatory approval requires biosimilars to demonstrate equivalence in clinical endpoints and immunogenicity. Solid evidence supports confident substitution and switching.
Seth: The study was a multicentre, randomized, double-blind, parallel-group trial across international sites, enhancing generalizability.
Britany: Inclusion criteria: adults ≥18 years with PASI ≥12, body surface area ≥10%, Investigator’s Global Assessment ≥3, stable disease ≥6 months, and inadequate response or intolerance to systemic treatment.
Seth: Randomization was 1:1 to FYB202 or reference ustekinumab. Double-blinding was maintained with identical packaging and administration to minimize bias.
Britany: Both groups received weight-based dosing at weeks 0 and 4, then every 12 weeks. At week 28, responders in the reference group were re-randomized to continue reference or switch to FYB202, assessing switching impact.
Seth: The primary outcome was percent PASI improvement from baseline to week 12. Secondary outcomes included safety, tolerability, anti-drug antibodies, injection site reactions, and immunogenicity up to week 28.
Britany: Equivalence margins were predefined. Least-squares mean differences with 90% and 95% confidence intervals were calculated, with intent-to-treat and per-protocol analyses. Subgroup analyses were done.
Seth: Key findings: mean PASI improvement at week 12 was equivalent between FYB202 and reference ustekinumab. The treatment difference was 3.27%, within equivalence margins.
Britany: Safety profiles were comparable. Injection site pain was most frequent—11.2% in FYB202 vs. 7.7% in reference group—mostly mild and after the first injection.
Seth: Immunogenicity was similar. Anti-drug antibody incidence was slightly lower in FYB202; titers were low and comparable. Switching did not affect efficacy, safety, or immunogenicity.
Britany: This reassures clinicians about switching. The switch substudy shows no increased risk or loss of efficacy after transition.
Seth: Related research like the VESPUCCI trial (Papp et al., 2025) and the SB17 Phase III study (2023) also demonstrated therapeutic equivalence and similar safety profiles.
Britany: Other biosimilars such as CT-P43 and ABP 654 show consistent efficacy, safety, and immunogenicity, supporting ustekinumab biosimilars as effective, safe, and cost-effective alternatives.
Seth: Clinically, educating patients about mild injection site pain after the first dose and reassuring them about immunogenicity can improve adherence and acceptance.
Britany: Pharmacists should monitor patients post-switch but can be confident no increased risk is expected, supporting biosimilar substitution policies and reducing costs without compromising care.
Seth: The study included adults with stable disease ≥6 months but excluded those with significant comorbidities or unstable psoriasis, so caution is needed when applying results to complex cases.
Britany: Drug interactions weren’t a focus, but clinicians should be cautious with concomitant immunosuppressants or live vaccines due to ustekinumab’s immunomodulatory effects.
Seth: Strengths include randomized, double-blind design, adequate sample size (392 patients), and a switch substudy. Limitations are the short primary endpoint (12 weeks) and immunogenicity assessment mostly up to 28 weeks, leaving long-term effects less clear.
Britany: Longer-term data beyond 52 weeks and real-world evidence would help confirm sustained efficacy and safety.
Seth: Also, no direct head-to-head trials comparing different ustekinumab biosimilars exist, which could guide biosimilar selection.
Britany: In summary, FYB202 showed therapeutic equivalence to reference ustekinumab with PASI 90 response rates near 80% and Investigator’s Global Assessment scores of 0 or 1 in about 80% of patients. Safety and immunogenicity were similar, supporting its role as an effective, safe option.
Seth: This evidence empowers pharmacists and physicians to confidently use biosimilar ustekinumab, improving affordability and access for moderate-to-severe plaque psoriasis patients.
Britany: Thanks for the discussion, Seth. Listeners can review the full study by Papp et al. in Advances in Therapy, 2025. Links are in the show notes.
Seth: Thanks, Britany. It’s exciting to see biosimilars gaining strong evidence, helping optimize care while managing resources.
Britany: That’s today’s PACULit update. Stay tuned for more evidence-based reviews. Until next time, keep advancing your practice with the latest science.
Seth: Take care, everyone!
Britany: Before we wrap up, Seth, what do you think are the implications of this study for healthcare systems and payers?
Seth: Great question, Britany. Biosimilars like FYB202 have the potential to substantially reduce healthcare costs associated with biologic therapies. Given that psoriasis is a chronic condition requiring long-term treatment, even modest price reductions can translate into significant savings at the population level. This can improve access for patients who might otherwise face financial barriers.
Britany: Absolutely. And from a policy perspective, having robust clinical data supporting biosimilar interchangeability can encourage formulary inclusion and reimbursement, which further drives uptake.
Seth: Right. Plus, as more biosimilars enter the market, competition may lead to further price reductions. But it’s crucial that clinicians and patients trust these agents, which is why studies like this one are so important.
Britany: Speaking of patient trust, what strategies do you recommend for clinicians to address patient concerns about switching from a reference biologic to a biosimilar?
Seth: Transparency is key. Clinicians should explain that biosimilars undergo rigorous testing to ensure they match the reference product in safety and efficacy. Sharing data from switch studies can reassure patients that switching won’t compromise their treatment. Also, monitoring patients closely after the switch and encouraging open communication helps manage any concerns or adverse events promptly.
Britany: That makes sense. It’s also important to highlight the potential benefits, such as improved access and reduced out-of-pocket costs, which can motivate patients to accept biosimilars.
Seth: Exactly. And pharmacists play a vital role here too, as they often are the last healthcare professional patients interact with before receiving their medication. Pharmacists can reinforce education, monitor for side effects, and report any issues.
Britany: On a related note, do you think biosimilars will eventually become the standard first-line biologic therapy for psoriasis?
Seth: It’s possible, especially as more biosimilars demonstrate equivalence and gain regulatory approval. Cost-effectiveness will be a strong driver. However, individual patient factors and clinician preference will still influence initial therapy choices. Over time, as confidence grows, biosimilars may become the default option.
Britany: Looking ahead, what areas of research do you think are needed to further support biosimilar use in dermatology?
Seth: Long-term real-world studies are essential to confirm sustained efficacy and safety beyond clinical trial settings. Also, more data on switching multiple times between biosimilars and reference products would be valuable, as patients may change therapies for various reasons. Additionally, studies in special populations, such as those with comorbidities or pediatric patients, would help broaden applicability.
Britany: Those are important points. It will also be interesting to see pharmacoeconomic analyses that quantify cost savings and impact on healthcare resource utilization.
Seth: Definitely. Integrating clinical outcomes with economic data can guide policy decisions and optimize resource allocation.
Britany: Well, Seth, this has been a comprehensive discussion. Thanks again for sharing your insights on this important topic.
Seth: My pleasure, Britany. Looking forward to our next update.
Britany: And thank you to our listeners for tuning in to PACULit. Don’t forget to check out the show notes for links to the full study and related resources. Stay informed and keep advancing your clinical practice.
Seth: Take care, everyone!